Works matching IS 13419625 AND DT 2023 AND VI 28 AND IP 5
Results: 13
Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 613, doi. 10.1007/s10147-023-02326-w
- By:
- Publication type:
- Article
Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 680, doi. 10.1007/s10147-023-02325-x
- By:
- Publication type:
- Article
Clinical value of minimum apparent diffusion coefficient for prediction of clinically significant prostate cancer in the transition zone.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 716, doi. 10.1007/s10147-023-02324-y
- By:
- Publication type:
- Article
Impact of MIR31HG polymorphisms on risk of breast cancer in Chinese women.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 664, doi. 10.1007/s10147-023-02323-z
- By:
- Publication type:
- Article
Strategy for PSA progression in patients undergoing salvage radiation for biochemical recurrence after radical prostatectomy.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 707, doi. 10.1007/s10147-023-02322-0
- By:
- Publication type:
- Article
Impact of skeletal muscle mass on the prognosis of patients undergoing neoadjuvant chemotherapy for resectable or borderline resectable pancreatic cancer.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 688, doi. 10.1007/s10147-023-02321-1
- By:
- Publication type:
- Article
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 654, doi. 10.1007/s10147-023-02318-w
- By:
- Publication type:
- Article
Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 644, doi. 10.1007/s10147-023-02316-y
- By:
- Publication type:
- Article
Anticancer drug therapy for patients with renal dysfunction.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 637, doi. 10.1007/s10147-023-02315-z
- By:
- Publication type:
- Article
Comparison of outcomes in high-risk prostate cancer patients treated with low-/high-dose-rate brachytherapy plus external beam radiotherapy.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 698, doi. 10.1007/s10147-023-02314-0
- By:
- Publication type:
- Article
Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists.
- Published in:
- International Journal of Clinical Oncology, 2023, v. 28, n. 5, p. 625, doi. 10.1007/s10147-023-02307-z
- By:
- Publication type:
- Article
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice